Journals / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 1

Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema

Pages
64–69
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was signifi cant difference observed between the initial and end of follow-up CFT (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To estimate the utilization of bevacizumab and to monitor disease in patients with the branch or central retinal vein occlusion (BRVO/ CRVO) and diabetic macular edema (DME) in clinical practice.
📊
Key Findings & Data:Material and methods: This hospital-based prospective study comprised 102 patients with macular edema with DME and RVO.
💡
Conclusion & Impact:There was signifi cant difference observed between the initial and end of follow-up CFT (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To estimate the utilization of bevacizumab and to monitor disease in patients with the branch or central retinal vein occlusion (BRVO/ CRVO) and diabetic macular edema (DME) in clinical practice. Material and methods: This hospital-based prospective study comprised 102 patients with macular edema with DME and RVO. Intravitreal injection of 1.25 mg/0.05ml Bevacizumab was administered following standard surgical protocol. All eyes were bi-microscopically examined preoperatively and post-operatively. Results: As per the optical coherence tomography (OCT) results of Central Foveal Thickness (CFT), the amount of CFT in DME patients reduced to 278.20 ± 68.91(initial: 511.02 ± 131.92); in BRVO patients, it was reduced to 219.04 ± 53.61 (initial: 425.83± 151.68); and in CRVO patients, it was reduced to 292.14 ± 46.99 (initial: 598.71 ± 87.27) after the injection at the end of 1 year. There was signifi cant difference observed between the initial and end of follow-up CFT (p

🔖

Cite This Article

SHARM, A., CHAKRABORT, P., KRISHN, T., CHAKRABORT, A. (2022). Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema. Retina-Vitreus, Cilt: 30 - Sayı: 1, 64–69. https://ajindex.com/articles/589045

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rogers S, McIntosh RL, Cheung N, et al. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9
  2. Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clinical Ophthalmology 2014; 8: 1611-21
  3. Noma H, Funatsu H, Mimura T, et al. Soluble Vascular Endothelial Growth Factor Receptor-2 and Infl ammatory Factors in Macular Edema with Branch Retinal Vein Occlusion. Am J Ophthalmol 2011; 152: 669-77
  4. Eldeeb M, Chan EW, Dedhia CJ, et al. One-year outcomes of zivafl ibercept for macular edema in central retinal vein occlusion. Am J Ophthalmol Case Rep. 2017: 58-61
  5. Arevalo JF, Sanchez JG, Lasave AF, et al. Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADA OF Lecture. J Ophthalmol. 2011;584238: 13
  6. Li Z, Bergen TV, de Veire SV, et al. Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery. Investig Ophthalmol Vis Sci. 2009;50:5217-25
  7. Manayath GJ, Narendran, V, Al-Kharousi N, wt al. Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results. Oman J Ophthalmol 2009; 2:73-8
  8. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010;4:809-16
  9. Braimah IZ, Singh SR, Uplanchiwar B, et al. Bevacizumab versus Ziv-afl ibercept in branch retinal vein occlusion. Indian J Ophthalmol. 2019;67:1109-13
  10. Paulose R, Chhablani J Dedhia CJ, et al. Intravitreal Zivafl ibercept for edema following retinal vein occlusion. Clin Ophthalmol. 2016;10:1853-58
  11. Slabaugh M, Salim S. Use of anti-VEGF agents in glaucoma surgery. J Ophthalmol 2017;1645269:11
  12. Vader MJC, Schauwvlieghe ME, Verbraak FD, et al. Comparing the effi cacy of Bevacizumab and Ranibizumab in patients with retinal vein occlusion. Ophthalmology Retina 2020; 4: 576-87
  13. Kumar A, Tripathy K, Chawla R. Intraocular use of bevacizumab in India: an issue resolved? The National Medical Journal of India 2017: 30: 345-47
  14. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. Ophthalmology 2006;113:1695-705
  15. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (AvastinR) for macular oedema secondary to retinal vein occlusion: 12 m